Trials / Completed
CompletedNCT05832333
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 Months
Post-marketing Surveillance Study for the Use of VaxigripTetra®, a Quadrivalent Influenza Vaccine Administered Via Intramuscular Route in Subjects Aged 6 to 35 Months in Republic of Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 682 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 6 Months – 35 Months
- Healthy volunteers
- Accepted
Summary
Multi-center, observational, active safety surveillance study in participants aged 6 to 35 months in Korea under routine clinical practices.
Detailed description
The planned duration of each participant's participation in the study will be 21 to 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VaxigripTetra® | Suspension for injection Injection intramuscular |
Timeline
- Start date
- 2019-10-05
- Primary completion
- 2022-02-07
- Completion
- 2022-02-07
- First posted
- 2023-04-27
- Last updated
- 2023-04-27
Locations
12 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05832333. Inclusion in this directory is not an endorsement.